

Dapagliflozin in STEMI

NCT06174753

Status	RECRUITING
Phase	Phase 3
Sponsor	Ottawa Heart Institute Research Corporation
Enrollment	256 participants

Key Eligibility Criteria

Inclusion (5)

- Patients referred for PPCI meeting the following criteria are eligible for the study:
- Ischemic chest discomfort of e30 minutes duration, and
- Onset of chest pain d12 hours prior to entry into the study, and
- One of the following High-Risk criteria on a standard 12 lead ECG:
 - a. Anterior STEMI with ST-segment elevation e2mm (0.2 mV) in each of at least 2 contiguous precordial leads (V1-V6) b. Extensive non-anterior STEMI defined as ST-segment elevation of ≥ 1 mm in two or more contiguous non-anterior leads accompanied by i. 8 or more leads with ≥ 1 mm ST elevation or depression, or both; OR ii. Sum of ST- segment elevation ≥ 20 mm

Exclusion (21)

- Age ≤ 18 years
- Any contraindication to undergo CMR imaging
- Killip 4 (Cardiogenic shock on presentation)
- Therapy with SGLT2i within last 8 weeks
- Type 1 diabetes mellitus
- ... and 16 more (see full listing online)

Locations (1 total)

University of Ottawa Heart Institute, Ottawa, Ontario, Canada